410086-25-8 Usage
General Description
1(2H)-Isoquinolinone,5-fluoro-(9CI) is a chemical compound that belongs to the class of isoquinolinones, which are heterocyclic compounds containing a benzene ring fused to a pyridine ring. The addition of a fluorine atom to the structure of the isoquinolinone molecule results in the formation of 5-fluoro-1(2H)-isoquinolinone. This chemical compound has potential applications in the field of medicinal chemistry, as fluorine substitution can alter the properties and biological activities of a molecule. It may serve as a building block for the synthesis of pharmaceuticals and agrochemicals, or as a research tool in the study of biological systems. The specific properties and potential uses of 5-fluoro-1(2H)-isoquinolinone would depend on its synthesis, purification, and characterization.
Check Digit Verification of cas no
The CAS Registry Mumber 410086-25-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,1,0,0,8 and 6 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 410086-25:
(8*4)+(7*1)+(6*0)+(5*0)+(4*8)+(3*6)+(2*2)+(1*5)=98
98 % 10 = 8
So 410086-25-8 is a valid CAS Registry Number.
410086-25-8Relevant articles and documents
Rhodium(III)-catalyzed C-H activation/annulation with vinyl esters as an acetylene equivalent
Webb, Nicola J.,Marsden, Stephen P.,Raw, Steven A.
, p. 4718 - 4721 (2015/04/27)
The behavior of electron-rich alkenes in rhodium-catalyzed C-H activation/annulation reactions is investigated. Vinyl acetate emerges as a convenient acetylene equivalent, facilitating the synthesis of sixteen 3,4-unsubstituted isoquinolones, as well as select heteroaryl-fused pyridones. The complementary regiochemical preferences of enol ethers versus enol esters/enamides is discussed.
HEPATITIS C VIRUS INHIBITORS
-
Page 337-338, (2008/06/13)
Hepatitis C virus inhibitors are disclosed having the general formula:(I) wherein R1, R2, R3, R', B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds toinhibit HCV are also disclosed.
